Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
3.12M
-
Number of holders
-
43
-
Total 13F shares, excl. options
-
38.7M
-
Shares change
-
-1.51M
-
Total reported value, excl. options
-
$27.1M
-
Value change
-
-$1.52M
-
Put/Call ratio
-
0
-
Number of buys
-
17
-
Number of sells
-
-15
-
Price
-
$0.70
Significant Holders of Passage BIO, Inc. - COMMON STOCK (PASG) as of Q3 2024
52 filings reported holding PASG - Passage BIO, Inc. - COMMON STOCK as of Q3 2024.
Passage BIO, Inc. - COMMON STOCK (PASG) has 43 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 38.7M shares
.
Largest 10 shareholders include ORBIMED ADVISORS LLC (9.82M shares), Lynx1 Capital Management LP (8.43M shares), Vestal Point Capital, LP (6.1M shares), New Leaf Venture Partners, L.L.C. (2.5M shares), Erste Asset Management GmbH (2.46M shares), VANGUARD GROUP INC (2.07M shares), TANG CAPITAL MANAGEMENT LLC (1.5M shares), RENAISSANCE TECHNOLOGIES LLC (1.39M shares), ACADIAN ASSET MANAGEMENT LLC (961K shares), and BlackRock, Inc. (722K shares).
This table shows the top 43 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.